Cutaneous sarcoidosis therapy updated

Journal of the American Academy of Dermatology

Volumn 56, Issue 1, 2007, Pages 69-83

  Badgwell, Christy ^a   Rosen, Ted ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIMALARIAL AGENT; AZATHIOPRINE; BETAMETHASONE DIPROPIONATE; CHLORAMBUCIL; CHLOROQUINE; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOSPORIN A; DOXYCYCLINE; FOLIC ACID; HYDROXYCHLOROQUINE; INFLIXIMAB; ISOTRETINOIN; LEFLUNOMIDE; MELATONIN; METHOTREXATE; MINOCYCLINE; OLMESARTAN; PENTOXIFYLLINE; PREDNISONE; TETRACYCLINE; THALIDOMID; THALIDOMIDE; TRIAMCINOLONE; ULOBETASOL PROPIONATE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACNE; AGRANULOCYTOSIS; ALLERGIC PNEUMONITIS; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLEEDING TENDENCY; BLOOD TOXICITY; BLURRED VISION; BONE MARROW SUPPRESSION; BRADYCARDIA; CHEILITIS; CHOLESTEROL BLOOD LEVEL; CHROMOSOME DAMAGE; CLAUDICATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CUSHINGOID SYNDROME; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY NOSE; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM LEPROSUM; EUPHORIA; EXFOLIATIVE DERMATITIS; FEVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GLUCOSE INTOLERANCE; GOUT; HAIR DISCOLORATION; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; HYPERPIGMENTATION; HYPERTENSION; HYPOPIGMENTATION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHERMIA; INCREASED APPETITE; INDUCED HYPOTENSION; INFECTION; INSOMNIA; INTERSTITIAL PNEUMONIA; LASER SURGERY; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; LYMPHADENOPATHY; LYMPHOMA; MALAISE; META ANALYSIS; MOOD DISORDER; MOUTH PAIN; MUCOSA INFLAMMATION; MYALGIA; MYCOSIS; NAUSEA; NEUTROPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PEPTIC ULCER; PERIPHERAL NEUROPATHY; PHOTOTOXICITY; PREGNANCY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PSYCHOSIS; RECOMMENDED DRUG DOSE; RESTLESSNESS; RETINA MACULOPATHY; RETINOPATHY; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SIDE EFFECT; SKIN ATROPHY; SKIN DISEASE; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TERATOGENESIS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT INDICATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; TUBERCULOSIS; VAGINA CANDIDIASIS; VOMITING; WOUND HEALING IMPAIRMENT; XEROSIS;

ABNORMALITIES, DRUG-INDUCED; ADRENAL CORTEX HORMONES; ALLOPURINOL; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; ANTIMALARIALS; CHLORAMBUCIL; CYCLOSPORINE; CYTOKINES; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; LASER SURGERY; MALE; MELATONIN; METHOTREXATE; MODELS, IMMUNOLOGICAL; PENTOXIFYLLINE; PREGNANCY; PREGNANCY COMPLICATIONS; SARCOIDOSIS; SKIN DISEASES; TETRACYCLINES; TH1 CELLS; THALIDOMIDE;

EID: 33845788102     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.06.019     Document Type: Article

References (142)

1. Chensue S.W., Warmington K., Ruth J., Lincoln P., Kuo M.C., and Kunkel S.L. Cytokine responses during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. Production of Th1 and Th2 cytokines and relative contribution of tumor necrosis factor. Am J Path 145 (1994) 1105-1113
2. Moller D.R. Treatment of sarcoidosis-from a basic science point of view. J Intern Med 253 (2003) 31-40
3. Muller-Quernheim J. Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J 12 (1998) 716-738
4. Moller D.R., Forman J.D., Liu M.C., Noble P.W., Greenlee B.M., Vyas P., et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 156 (1996) 4952-4960
5. Moller D.R. Involvement of T-cells and alterations in T-cell receptors in sarcoidosis. Semin Respir Infect 13 (1998) 174-183
6. Peckman D.G., and Spiteri M.A. Sarcoidosis. Postgrad Med J 72 (1996) 196-200
7. Crystal R.G. Sarcoidosis. In: Kasper D.L., Fauci A.S., Longo D.L., Braunwald E., Hauser S.L., and Jameson J.L. (Eds). Harrison's principles of internal medicine. 16th ed. (2005), McGraw-Hill, New York 2017-2023
8. Baughman R.P., and Lynch J.P. Difficult treatment issues in sarcoidosis. J Intern Med 253 (2003) 41-45
9. Statement on sarcoidosis. The Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS), and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS board of directors and by the ERS executive committee, February 1999. Am J Respir Crit Care Med 160 (1999) 736-755
10. Albertini J.G., Tyler W., and Miller III O.F. Ulcerative sarcoidosis: case report and review of the literature. Arch Dermatol 133 (1997) 215-219
11. Adcock I.M. Molecular mechanisms of glucocorticosteroid actions. Pulm Pharmacol Ther 13 (2000) 115-126
12. Woronicz J.D., Gao X., Cao Z., Rothe M., and Goeddel D.V. IkB kinase-beta: NF-kB activation and complex formation with IkB kinase-alpha and NIK. Science 278 (1997) 866-869
13. Milburn H.J., Poulter L.W., Dilmec A., Cochrane G.M., and Kemeny D.M. Corticosteroids restore the balance between locally produced Th1 and Th2 cytokines and immunoglobulin isotypes to normal in sarcoid lung. Clin Exp Immunol 108 (1997) 105-113
14. Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Derm Venereol 72 (1992) 69-71
15. Khatri K.A., Chotzen V.A., and Burrall B.A. Lupus pernio: successful treatment with a potent topical corticosteroid. Arch Dermatol 131 (1995) 617-618
16. Russo G., and Millikan L.E. Cutaneous sarcoidosis: diagnosis and treatment. Compr Ther 20 (1994) 418-421
17. Verbov J. The place of intralesional steroid therapy in dermatology. Br J Dermatol 94 suppl 12 (1976) 51-58
18. English III J.C., Patel P.J., and Greer K.E. Sarcoidosis. J Am Acad Dermatol 44 (2001) 725-743
19. Veien N.K. Cutaneous sarcoidosis: prognosis and treatment. Clin Dermatol 4 (1986) 75-87
20. In: Mycek M.J., Harvey R.A., Champe P.C., Fisher B.D., and Cooper M. (Eds). Lippincott's illustrated reviews: pharmacology. 2nd ed. (1997), Lippincott Williams & Wilkins, Philadelphia
21. Siltzbach L.E. Effects of cortisone in sarcoidosis. A study of thirteen patients. Am J Med 12 (1952) 139-160
22. Baughman R.P., and Lower E.E. Steroid-sparing alternative treatments for sarcoidosis. Clin Chest Med 18 (1997) 853-864
23. Fox R.I., and Kang H.I. Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation. Lupus 2 suppl 1 (1993) S9-S12
24. Siltzbach L.E., and Teirstein A.S. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand 176 suppl 425 (1964) 302-306
25. Morse S.I., Cohn Z.A., Hirsch J.G., and Schaedler R.W. The treatment of sarcoidosis with chloroquine. Am J Med 30 (1961) 779-784
26. British Tuberculosis Association. Chloroquine in the treatment of sarcoidosis. A report from the research committee of the British Tuberculosis Association. Tubercle 48 (1967) 257-272
27. Zic J.A., Horowitz D.H., Arzubiaga C., and King Jr. L.E. Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature. Arch Dermatol 127 (1991) 1034-1040
28. Jones E., and Callen J.P. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol 23 (1990) 487-489
29. Liedtka J.E. Intralesional chloroquine for the treatment of cutaneous sarcoidosis. Int J Dermatol 35 (1996) 682-683
30. Burns R.P. Delayed onset of chloroquine retinopathy. N Engl J Med 275 (1966) 693-696
31. Rigaudiere F., Ingster-Moati I., Hache J.C., Leid J., Verdet R., Haymann P., et al. Updated ophthalmological screening and follow-up management for long-term antimalarial treatment. [in French]. J Fr Ophtalmol 27 (2004) 191-199
32. Olansky A.J. Antimalarials and ophthalmologic safety. J Am Acad Dermatol 6 (1982) 19-23
33. Ochsendorf F.R., and Runne U. Chloroquine: consideration of maximum daily dose (3.5 mg/kg ideal body weight) prevents retinopathy. Dermatology 192 (1996) 382-383
34. Jones S.K. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol 140 (1999) 3-7
35. Grierson D.J. Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis 56 (1997) 188-190
36. Mavrikakis I., Sfikakis P.P., Mavrikakis E., Rougas K., Nikolaou A., Kostopoulos C., et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology 110 (2003) 1321-1326
37. Cronstein B.N. The mechanism of action of methotrexate. Rheum Dis Clin N Am 23 (1997) 739-753
38. Lower E.E., and Baughman R.P. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci 299 (1990) 153-157
39. Webster G.F., Razsi L.K., Sanchez M., and Shupack J.L. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol 24 (1991) 451-454
40. Lower E.E., and Baughman R.P. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 155 (1995) 846-851
41. Baughman R.P., and Lower E.E. A clinical approach to the use of methotrexate for sarcoidosis. Thorax 54 (1999) 742-746
42. Shiroky J.B. The use of folates concomitantly with low-dose pulse methotrexate. Rheum Dis Clin 23 (1997) 969-979
43. Hassan W. Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists. Ann Rheum Dis 55 (1996) 273-275
44. Mosam A., and Morar N. Recalcitrant cutaneous sarcoidosis: an evidence-based sequential approach. J Dermatol Treat 15 (2004) 353-359
45. Baughman R.P., and Iannuzzi M. Tumor necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs 17 (2003) 425-431
46. Marques L.J., Zheng L., Poulakis N., Guzman J., and Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med 159 (1999) 508-511
47. Tong Z., Dai H., Chen B., Abdoh Z., Guzman J., and Costabel U. Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline. Comparison with dexamethasone. Chest 124 (2003) 1526-1532
48. Korber M., Kamp S., Kothe H., Braun J., and Dalhoff K. Pentoxifylline inhibits secretion of O2- and TNF-alpha by alveolar macrophages in patients with sarcoidosis. [in German]. Immun Infekt 23 (1995) 107-110
49. Moller D.R., Wysocka M., Greenlee B.M., Ma X., Wahl L., Trinchieri G., et al. Inhibition of human interleukin-12 production by pentoxifylline. Immunol 91 (1997) 197-203
50. Zabel P., Entzian P., Dalhoff K., and Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 155 (1997) 1665-1669
51. Inoue K., Hirohisa T., Yanagisawa R., and Sakurai M. Anti-inflammatory effect of pentoxifylline. Chest 126 (2004) 321
52. Marshall T.G., and Marshall F.E. Sarcoidosis succumbs to antibiotics-implications for autoimmune disease. Autoimmun Rev 3 (2004) 295-300
53. Marshall T.G., and Marshall F.E. Antibiotics in sarcoidosis-reflections of the first year. J Indep Med Res 1 (2003) 2. Available at: http://www.joimr.org/phorum/read.php?f=2&i=38&t=38 Accessed April 2, 2006
54. Webster G.F., Toso S.M., and Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. Arch Dermatol 130 (1994) 748-752
55. Kelly K.J., Sutton T.A., Weathered N., Ray N., Caldwell E.J., Plotkin Z., et al. Minocycline inhibits apoptosis and inflammation in a rat model of ischemic renal injury. Am J Physiol Renal Physiol 287 (2004) F760-F766
56. Thong Y.H., and Ferrante A. Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogues. Clin Exp Immunol 35 (1979) 443-446
57. Thong Y.H., and Ferrante A. Effect of tetracycline treatment on immunologic responses in mice. Clin Exp Immunol 39 (1980) 728-732
58. Bikowski J.B. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed 2 (2003) 234-245
59. Bachelez H., Senet P., Cadranel J., Kaoukhov A., and Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 137 (2001) 69-73
60. Veien N.K., Stahl D., and Brodthagen H. Granulomatous rosacea treated with tetracycline. Dermatologica 163 (1981) 267-269
61. Falk E.S. Sarcoid-like granulomatous periocular dermatitis treated with tetracycline. Acta Derm Venereol 65 (1985) 270-272
62. Massacesi L., Castigli E., Vergelli M., Olivotto J., Abbamondi A.L., Sario F., et al. Immunosuppressive activity of 13-cis-retinoic acid and prevention of experimental autoimmune encephalomyelitis in rats. J Clin Invest 88 (1991) 1331-1337
63. Dupuy P., Bagot M., Heslan M., and Dubertret L. Synthetic retinoids inhibit the antigen presenting properties of epidermal cells in vitro. J Invest Dermatol 93 (1989) 455-459
64. Waldinger T.P., Ellis C.N., Quint K., and Voorhees J.J. Treatment of cutaneous sarcoidosis with isotretinoin. Arch Dermatol 119 (1983) 1003-1005
65. Vaillant L., le Marchand D., Bertrand S., Grangeponte M.C., and Lorette G. Annular cutaneous sarcoidosis of the forehead: treatment with isotretinoin. [in French]. Ann Derm Venereol 113 (1986) 1089-1092
66. Georgiou S., Monastirli A., Pasmatzi E., and Tsambaos D. Cutaneous sarcoidosis: complete remission after oral isotretinoin therapy. Acta Derm Venereol 78 (1998) 457-459
67. Chong W.S., Tan H.H., and Tan S.H. Cutaneous sarcoidosis in Asians: a report of 25 patients from Singapore. Clin Exp Dermatol 30 (2005) 120-124
68. Goodfield M, Cox N, Dudley A, Mc Millian C, Millard L, Simpson N. Clinical guidelines. Advice on the safe introduction and continued use of isotretinoin in acne. Available at: http://www.bad.org.uk/healthcare/guidelines/acne.asp. Accessed June 29, 2005.
69. Breedveld F.C., and Dayer J.M. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 59 (2000) 841-849
70. Majithia V., Sanders S., Harisdangkul V., and Wilson J.G. Successful treatment of sarcoidosis with leflunomide. Rheumatology (Oxford) 42 (2003) 700-702
71. Baughman R.P., and Lower E.E. Leflunomide for chronic sarcoidosis. Sarcoid Vasc Diffuse Lung Dis 21 (2004) 43-48
72. Chong A.S.F., Huang W., Liu W., Luo J., Shen J., Xu W., et al. In vivo activity of leflunomide. Pharmacokinetic analyses and mechanism of immunosuppression. Transplantation 68 (1999) 100-109
73. Fischer T.W., Bauer H.I., Graefe T., Barta U., and Elsner P. Erythema multiforme-like drug eruption with oral involvement after intake of leflunomide. Dermatol 207 (2003) 386-389
74. Bandyopadhyay D. Exfoliative dermatitis induced by leflunomide therapy. J Dermatol 30 (2003) 845-846
75. McHugh S.M., Rifkin I.R., Deighton J., Wilson A.B., Lachmann P.J., Lockwood C.M., et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99 (1995) 160-167
76. Meierhofer C., Dunzendorfer S., and Wiedermann C.J. Theoretical basis for the activity of thalidomide. BioDrugs 15 (2001) 681-703
77. Perri AJ III, Hsu S. A review of thalidomide's history and current dermatologic applications. Dermatology Online Journal. Available at: http://dermatology.cdlib.org. Accessed April 2, 2006.
78. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., and Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173 (1991) 699-703
79. Tavares J.L., Wangoo A., Dilworth P., Marshall B., Kotecha S., and Shaw R.J. Thalidomide reduces tumor necrosis factor-alpha production by human alveolar macrophages. Respir Med 91 (1997) 31-39
80. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., and Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177 (1993) 1675-1680
81. Barriere H. Cutaneous sarcoidosis. Treatment with thalidomide. [in French]. Presse Med 12 (1983) 963
82. Carlesimo M., Giustini S., Rossi A., Bonaccorsi P., and Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 32 (1995) 866-869
83. Rousseau L., Beylot-Barry M., Doutre M.S., and Beylot C. Cutaneous sarcoidosis successfully treated with low dose of thalidomide. Arch Dermatol 134 (1998) 1045-1046
84. Grasland A., Pouchot J., Chaumaiziere D., Aitken G., and Vinceneuz P. Effectiveness of thalidomide treatment during cutaneous sarcoidosis. [in French]. Rev Med Interne 19 (1998) 208-209
85. Lee J.B., and Koblenzer P.S. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol 39 (1998) 835-838
86. Baughman R.P., Judson M.A., Teirstein A.S., Moller D.R., and Lower E.E. Thalidomide for chronic sarcoidosis. Chest 122 (2002) 227-232
87. Oliver S.J., Kikuchi T., Kreuger J.G., and Kaplan G. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol 102 (2002) 225-236
88. Nguyen Y.T., Dupuy A., Cordoliani F., Vignon-Pennamen M.D., Lebbe C., Morel P., et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol 50 (2004) 235-241
89. Bastuji-Garin S., Ochonisky S., Bouche P., Gherardi R., Duguet C., Djerradine Z., et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol 119 (2002) 1020-1026
90. Scallon B., Cai A., Solowski N., Rosenburg A., Song X.Y., Shealy D., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharm Exp Ther 301 (2002) 418-426
91. Baughman R.P., and Lower E.E. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 18 (2001) 70-74
92. Meyerle J.H., and Shorr A. The use of infliximab in cutaneous sarcoidosis. J Drugs Dermatol 2 (2003) 413-414
93. Mallbris L., Ljungberg A., Hedblad M.A., Larsson P., and Stahle-Backdahl M. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol 48 (2003) 290-293
94. Roberts S.D., Wilkes D.S., Burgett R.A., and Knox K.S. Refractory sarcoidosis responding to infliximab. Chest 124 (2003) 2028-2031
95. Haley H., Cantrell W., and Smith K. Infliximab therapy for sarcoidosis (lupus pernio). Br J Dermatol 150 (2004) 146-149
96. Katz J.M., Bruno M.K., Winterkorn J.M.S., and Nealon N. The pathogenesis and treatment of optic disc swelling in neurosarcoidosis. A unique therapeutic response to infliximab. Arch Neurol 60 (2003) 426-430
97. Yee A.M.F., and Pochapin M.B. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 135 (2001) 27-31
98. Ulbricht K.U., Stoll M., Bierwirth J., Witte T., and Schmidt R.E. Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis Rheum 48 (2003) 3542-3543
99. Pritchard C., and Nadarajah K. Tumor necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 63 (2004) 318-320
100. Doty J.D., Mazur J.E., and Judson M.A. Treatment of sarcoidosis with infliximab. Chest 127 (2005) 1064-1071
101. Keane J., Sharon G., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor-necrosis factor (alpha)-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
102. Wallis R.S., Broder M.S., Wong J.Y., Hanson M.E., and Beenhouwer D.O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38 (2004) 1261-1265
103. Jackson C.G., and Williams H.J. Disease-modifying antirheumatic drugs. Using their clinical pharmacological effects as a guide to their selection. Drugs 56 (1998) 337-344
104. Kataria Y.P. Chlorambucil in sarcoidosis. Chest 78 (1980) 36-43
105. Isreal H.L., and McComb B.L. Chlorambucil treatment of sarcoidosis. Sarcoidosis 8 (1991) 35-41
106. Sahgal S.M., and Sharma O.P. Fatal herpes simplex infection during chlorambucil therapy for sarcoidosis. J R Soc Med 77 (1984) 144-146
107. Chen Q., and Wei W. Effects and mechanisms of melatonin on inflammatory and immune responses of adjuvant arthritis rat. Int Immunopharmacol 2 (2002) 1443-1449
108. Di Stefano A., and Paulesu L. Inhibitory effect of melatonin on production of IFN-gamma or TNF-alpha in peripheral blood mononuclear cells of some blood donors. J Pineal Res 17 (1994) 164-169
109. Arzt E.S., Fernandez-Castelo S., Finocchiaro L.M.E., Criscuolo M.E., Diaz A., Finkielman S., et al. Immunomodulation by indoleamines: serotonin and melatonin action on DNA and interferon-gamma synthesis by human peripheral blood mononuclear cells. J Clin Immunol 8 (1988) 513-520
110. Liu F., Ng T.B., and Fung M.C. Pineal indoles stimulate the gene expression of immunomodulating cytokines. J Neural Transm 108 (2001) 397-405
111. Cagnoni M.L., Lombardi A., Cerinic M.M., Dedola G.L., and Pignone A. Melatonin for treatment of chronic refractory sarcoidosis. Lancet 346 (1995) 1229-1230
112. Mulchahey J.J., Goldwater D.R., and Zemlan F.P. A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin. Life Sci 75 (2004) 1843-1856
113. Martinet Y., Pinkston P., Saltini C., Spurzem J., Muller-Quernheim J., and Crystal R.G. Evaluation of the in vitro and in vivo effects of cyclosporine on the T-lymphocyte alveolitis of active pulmonary sarcoidosis. Am Rev Repir Dis 138 (1988) 1242-1248
114. Ho S., Clipstone N., Timmerman L., Northrop J., Graef I., Fiorentino D., et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 80 (1996) S40-S45
115. Rebuck A.S., Stiller C.R., Braude A.C., Laupacis A., Cohen R.D., and Chapman K.R. Cyclosporin for pulmonary sarcoidosis. Lancet 1 (1984) 1174
116. O'Callaghan C.A., Wells A.U., Lalvani A., Dhillon P.D., Hansell D.M., and Mitchell D.N. Effective use of cyclosporin in sarcoidosis: a treatment strategy based on computed tomography scanning. Eur Respir J 7 (1994) 2255-2256
117. Rebuck A.S., Sanders B.R., MacFadden D.K., Man S.F.P., York E.L., and Cohen R.D. Cyclosporin in pulmonary sarcoidosis. Lancet 1 (1987) 1486
118. Losada A., Garcia-Doval I., de la Torre C., and Cruces M.J. Subcutaneous sarcoidosis worsened by cyclosporin treatment for pyoderma gangrenosum. Br J Dermatol 138 (1998) 1091-1104
119. Wyser C.P., van Schalkwyk E.M., Alheit B., Bardin P.G., and Joubert J.R. Treatment of progressive pulmonary sarcoidosis with cyclosporin A. Am J Respir Crit Care Med 156 (1997) 1371-1376
120. Kahan B.D. Cyclosporine. N Engl J Med 321 (1989) 1725-1738
121. Mizuno K., Okamoto H., and Horio T. Inhibitory influences of xanthine oxidase inhibitor and angiotensin I-converting enzyme inhibitor on multinucleated giant cell formation from monocytes by downregulation of adhesion molecules and purinergic receptors. Br J Dermatol 150 (2004) 205-210
122. Mizuno K., Okamoto H., and Horio T. Heightened ability of monocytes from sarcoidosis to form multi-nucleated giant cells in vitro by supernatants of concanavalin A-stimulated mononuclear cells. Clin Exp Immunol 126 (2001) 151-156
123. Rosef B.M. Allopurinol for sarcoid?. N Engl J Med 294 (1976) 447
124. Pollock J.L. Sarcoidosis responding to allopurinol. Arch Dermatol 116 (1980) 273-274
125. Samuel M., Allen G.E., McMillian S.C., Burrows D., Corbett J.R., and Beare J.M. Sarcoidosis: initial results on six patients treated with allopurinol. Br J Dermatol 111 suppl 26 (1984) 20
126. Brechtel B., Haas N., Henz B.M., and Kolde G. Allopurinol: a therapeutic alternative for disseminated cutaneous sarcoidosis. Br J Dermatol 135 (1996) 307-309
127. Antony F., and Layton A.M. A case of cutaneous acral sarcoidosis with response to allopurinol. Br J Dermatol 142 (2000) 1052-1053
128. El-Euch D., Mokni M., Trojjet S., Khouaja A., and Osman A.B. Sarcoidosis in a child treated successfully with allopurinol. Br J Dermatol 140 (1999) 1184-1185
129. Pfau A., Stolz W., Karrer S., Szeimies R.M., and Landthaler M. Allopurinol in treatment of cutaneous sarcoidosis. [in German]. Hautarzt 49 (1998) 216-218
130. Breghoej A., and Jemec G.B. Low-dose allopurinol in the treatment of cutaneous sarcoidosis: response in four of seven patients. J Dermatolog Treat 16 (2005) 125-127
131. Voelter-Mahlknecht S., Benez A., Metzger S., and Fierlbeck G. Treatment of subcutaneous sarcoidosis with allopurinol. Arch Dermatol 135 (1999) 1560-1561
132. James J.C., and Simpson C.B. Treatment of laryngeal sarcoidosis with CO2 laser and mitomycin-C. Otolaryngol Head Neck Surg 130 (2004) 262-264
133. Grema H., Greve B., and Raulin C. Scar sarcoidosis-treatment with the Q-switched ruby laser. Lasers Surg Med 30 (2002) 398-400
134. O'Donoghue N.B., and Barlow R.J. Laser remodeling of nodular nasal lupus pernio. Clin Exp Dermatol 31 (2006) 27-29
135. Goodman M.M., and Alpern K. Treatment of lupus pernio with the flashlamp pulsed dye laser. Lasers Surg Med 12 (1992) 549-551
136. Cliff S., Felix R.H., Singh L., and Harland C.C. The successful treatment of lupus pernio with the flashlamp pulsed dye laser. J Cutan Laser Ther 1 (1999) 49-52
137. 2 laser excision of lupus pernio of the face. Am J Otolaryngol 17 (1996) 260-263
138. 2 laser vaporization for disfiguring lupus pernio. J Cosmet Laser Ther 4 (2002) 87-90
139. Green J.J., Lawrence N., and Heymann W.R. Generalized ulcerative sarcoidosis induced by therapy with the flashlamp-pumped pulsed dye laser. Arch Dermatol 137 (2001) 507-508
140. Kormeili T., Neel V., and Moy R.L. Cutaneous sarcoidosis at sites of previous laser surgery. Cutis 73 (2004) 53-55
141. Berglund F., Flodh H., Lundborg P., Prame B., and Sannerstedt R. Drug use during pregnancy and breast-feeding. A classification system for drug information. Acta Obstet Gynecol Scand Suppl 126 (1984) 1-55
142. Brent R. Experts' answers. Health Physics Society. Available at: http://www.hps.org. Accessed January 19, 2006.